Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This study aims to evaluate the effect of angiotensin receptor/neprilysin inhibitors (ARNI) on improving ischemic mitral regurgitation (IMR) in patients with coronary artery disease undergoing isolated coronary artery bypass grafting (CABG) through a randomized controlled clincial trial.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Fully informed and voluntarily signed informed consent;
• Received CABG and moderate IMR was diagnosed on two consecutive preoperative transthoracic echocardiography (according to 2021 ESC/EACTS Guidance Standards )
Locations
Other Locations
China
China National Center for Cardiovascular Diseases
RECRUITING
Beijing
Contact Information
Primary
Lianxin Chen, M.D.
chenlianx1@163.com
010-88322265
Time Frame
Start Date: 2025-06-05
Estimated Completion Date: 2027-06
Participants
Target number of participants: 220
Treatments
No_intervention: Control group: isolated CABG
Experimental: Sacubitril/valsartan therapy after isolated CABG
Related Therapeutic Areas
Sponsors
Collaborators: Chinese Academy of Medical Sciences, Fuwai Hospital, Chinese Academy of Medical Sciences
Leads: China National Center for Cardiovascular Diseases